Inflammatory Bowel Disease Treatment Market Size Analysis - Market Share, Forecast Trends and Outlook Report (2024-2032)

Inflammatory Bowel Disease Treatment Market Outlook

• The increasing cases of Crohn's disease and ulcerative colitis along with the growing public awareness are fueling the demand for effective treatments. 
• The rising shift towards personalized medicine and the rise in strategic partnerships among the major pharmaceutical companies are significant market trends.
• Increased investment in research and development activities and the rising availability of biosimilars are anticipated to boost market size in the forecast period.

Inflammatory Bowel Disease Treatment Market Overview

Inflammatory bowel disease is a set of two disorders (ulcerative colitis and Crohn’s disease) causing chronic inflammation in the digestive system (particularly intestines). Common symptoms include abdominal pain, diarrhea, appetite loss, bloating, or blood in the stool. Immune system malfunction and gene mutation may be general causes of the disease. Inflammatory bowel disease treatment revolves around reducing inflammation. Medical professionals use anti-inflammatory drugs as a primary treatment source. Immune system suppressors, antibiotics, biologics, and surgery in extreme cases are common treatment methods.

With the rising prevalence of Crohn's disease and ulcerative colitis coupled with increasing government support for research, the inflammatory bowel disease treatment market is witnessing significant growth. Although the explicit etiopathogenesis of inflammatory bowel disease is still vague, researchers have been able to develop effective drugs and treatment alternatives with the help of a greater understanding of digestive physiology and technical advancements in biotechnology. This has fueled the demand for this treatment market further. Moreover, the increasing number of drugs under clinical trials and the rising popularity of pre-biotic and pro-biotic food products are likely to elevate the market value in the coming years.

Inflammatory Bowel Disease Treatment Market Growth Drivers

Increasing Prevalence of Inflammatory Bowel Disease Drives Market Growth

Inflammatory bowel disease poses a serious global health concern, affecting over 0.3% of the world population. In the United States, the prevalence of the disease is reported to be between 2.4 and 3.1 million, with the burden differing across groups within the population. Thus, the increasing prevalence of inflammatory bowel disease is one of the primary drivers of the market, which is propelling the demand for effective treatment options. Additionally, heightened public awareness and the advances in diagnostic capabilities are poised to support market growth.

Inflammatory Bowel Disease Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Rise in Mergers and Acquisitions Events to Affect the Market Landscape Significantly

To meet the rising market demand, healthcare giants across the 8 major markets are undergoing significant mergers and acquisitions. For instance, in October 2023, Sanofi and Teva announced their exclusive partnership to deliver inflammatory bowel disease treatment drugs. The collaboration combines Teva’s anti-TL1A therapy (developed to treat Crohn’s disease and ulcerative colitis) with Sanofi’s immunology strategy for exploring the action mechanism of chronic inflammatory diseases. The companies are aiming to commercialize and develop the TEV’574 drug together, which is currently in phase 2 trials.

In addition, Merck has also announced a USD 10.8 billion buy-out of Prometheus Biosciences, in order to access their anti-TL1A monoclonal antibody (mAb), which is entering a Phase III placebo-controlled study for Crohn’s and ulcerative colitis (UC). Such strategic mergers and acquisitions are expected to aid in market expansion.

Growth in Drug Approvals to Elevate Inflammatory Bowel Disease Treatment Market Value

In June 2024, American pharmaceutical company AbbVie announced that its interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab-rzaa) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis in adults. The regulatory approval also marked the expansion of AbbVie’s portfolio across inflammatory bowel disease treatments, which is poised to contribute to the market growth.

Growing Use of Biologics and Biosimilars to Augment the Inflammatory Bowel Disease Treatment Market Demand

Biologic drugs are widely used in the treatment of inflammatory bowel disease due to their ability to target specific molecules involved in the immune response. In addition, the market is experiencing a growing adoption of biosimilars, which are similar versions of biologics but are typically more affordable. Hence, the rising use of biologics and biosimilars is set to amplify market demand in the coming years.

Increasing Investment in Research and Development to Boost Inflammatory Bowel Disease Treatment Market Size

One of the major market trends is the rising investments in the development of novel therapies for inflammatory bowel disease. Leading pharmaceutical companies are focused on advancing pipeline drugs targeting new pathways, such as microbiome modulation, stem cell therapies, and gene editing techniques, which is anticipated to boost the market size in the forecast period. 

Inflammatory Bowel Disease Treatment Market Segmentation

Market Breakup by Disease Indication

• Ulcerative Colitis 
• Crohn’s Disease 

Market Breakup by Drug Class

• IL Inhibitors
• TNF Inhibitors
• Anti-integrin
• JAK Inhibitors
• Corticosteroids
• ASA Drugs
• Others

Market Breakup by Route of Administration

• Oral
• Injectable

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
• Japan
• India

Inflammatory Bowel Disease Treatment Market Share

The Drug Class Segment Holds a Substantial Market Share

Based on the drug class, the market is segmented into IL inhibitors, TNF inhibitors, anti-integrin, JAK inhibitors, corticosteroids, ASA drugs, and others. TNF (tumor necrosis factor) inhibitors hold a high market value owing to their widespread use in the treatment of both Crohn's disease and ulcerative colitis. These drugs have exhibited high efficacy in managing moderate to severe inflammatory bowel disease, especially in cases where the patients do not respond to conventional therapies.

Inflammatory Bowel Disease Treatment Market Analysis by Region

The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share, which can be attributed to the presence of an advanced healthcare infrastructure and high healthcare expenditure which allows the early access and adoption of newer biologics, small molecules, and other innovative treatments in the region. The availability of several biosimilars for inflammatory bowel disease also benefits the market growth. Moreover, the presence of strong regulatory support for novel drug approvals is one of the key factors aiding the market expansion in the country.

Leading Players in the Inflammatory Bowel Disease Treatment Market

The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Pfizer Inc.

Pfizer is a key player in the market, boasting a strong portfolio of drugs including its biologic Xeljanz (tofacitinib), a JAK inhibitor for the treatment of ulcerative colitis. The company is focused on expanding its biologics and targeted therapies pipeline for inflammatory bowel disease through strategic partnerships.

GlaxoSmithKline plc (GSK)

GlaxoSmithKline plc (GSK) has a prominent presence in the market and is investing in research and development to improve its biologics portfolio. The company is engaged in exploring immune-modulating therapies for combatting inflammatory bowel disease.

Novartis AG

Swiss multinational pharmaceutical corporation Novartis is a dominant player in the market and is working towards expanding indications for its existing drugs and developing new treatments aimed at improving long-term outcomes for inflammatory bowel disease.

Mylan N.V.

Mylan N.V., a generic and specialty pharmaceuticals company, is headquartered in Pennsylvania, United States. The company plays a significant role in improving access to biosimilars, especially in regions that are seeking cost-effective healthcare solutions for inflammatory bowel disease.

Other key players in the market include Teva Pharmaceutical Industries Ltd., Sanofi SA, AstraZeneca Plc, Janssen Pharmaceuticals Inc., Merck & Co., Baxter International Inc., Bayer AG, Eli Lilly and Company, AbbVie Inc., and Sun Pharmaceutical Industries Ltd. 

Key Questions Answered in the Inflammatory Bowel Disease Treatment Market Report

• What was the inflammatory bowel disease treatment market value in 2023?
• What is the inflammatory bowel disease treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on disease indication?
• What is the market breakup based on drug class?
• What is the market breakup by route of administration?
• What are the major distribution channels in the market?
• What are the major factors aiding the inflammatory bowel disease treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How do the prevalence and incidence of inflammatory bowel disease affect the market landscape?
• What are the major inflammatory bowel disease treatment market trends?
• How do the rising investments in research and development impact the market size?
• Which disease indication will dominate the market share? 
• Which drug class is expected to have a high market value in the coming years?
• Which route of administration will experience the highest demand in the market segment?
• Which distribution channel is projected to contribute to the highest market growth?
• Who are the key players involved in the inflammatory bowel disease treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?